For research use only. Not for therapeutic Use.
NMS-859 is a potent, covalent VCP (p97) inhibitor, with IC50s of 0.37 and 0.36 μM for wild-type VCP in the presence of 60 μM and 1 mM ATP in cells, respectively.
NMS-859 is a potent VCP inhibitor, with IC50s of 0.37 and 0.36 μM for wild-type VCP in the presence of 60 μM and 1 mM ATP in cells, respectively. NMS-859 shows very weak inhibitory activity against VCPC522T. NMS-859 also suppresses the proliferation of cells, with IC50s of 3.5 μM and 3.0 μM in HCT116 and HeLa cell lines, respectively[1].
| Catalog Number | I001740 |
| CAS Number | 1449236-96-7 |
| Synonyms | 2-chloro-N-[3-[(1,1-dioxo-1,2-benzothiazol-3-yl)amino]phenyl]acetamide |
| Molecular Formula | C15H12ClN3O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C15H12ClN3O3S/c16-9-14(20)17-10-4-3-5-11(8-10)18-15-12-6-1-2-7-13(12)23(21,22)19-15/h1-8H,9H2,(H,17,20)(H,18,19) |
| InChIKey | JWMFLBAPPIWNGG-UHFFFAOYSA-N |
| SMILES | C1=CC=C2C(=C1)C(=NS2(=O)=O)NC3=CC(=CC=C3)NC(=O)CCl |
| Reference | [1]. Magnaghi P, et al. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat Chem Biol. 2013 Sep;9(9):548-56. |
